چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | نعیمه مصری علمداری |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | مرکز تحقیقات غدد درون ریز |
| کد مقاله | 86521 |
| عنوان فارسی مقاله | Evaluation of the efficacy and safety of sitagliptin in overweight and obese adults with Type 2 Diabetes and moderate glycemic control: Results from the randomized double-blind controlled clinical trial |
| عنوان لاتین مقاله | Evaluation of the efficacy and safety of sitagliptin in overweight and obese adults with Type 2 Diabetes and moderate glycemic control: Results from the randomized double-blind controlled clinical trial |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | نهمین کنگره ملی پیشگیری و درمان چاقی ایران |
| نوع کنگره / همایش | ملی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | تهران |
| سال انتشار/ ارائه شمسی | 1403 |
| سال انتشار/ارائه میلادی | 2024 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1403/09/28 الی 1403/10/30 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://www.obesitycongress.ir/fa/ |
| آدرس علمی (Affiliation) نویسنده متقاضی | Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. |
| نویسنده | نفر چندم مقاله |
|---|---|
| نعیمه مصری علمداری | اول |
| پریسا جوانشیر | دوم |
| وحیده صدرا | سوم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Fasting plasma glucose, HbA1c, Sitagliptin, Safety, Type 2 diabetes |
| خلاصه مقاله | Background: The study aimed to measure the effectiveness and safety of adding sitagliptin to insulin/ metformin regimes in overweight and obese cases with moderately controlled type 2 diabetes mellitus (T2DM). Material and Methods: In a 12-week, randomized, controlled clinical trial, overweight/obese cases with T2DM were randomly assigned to provide either a placebo (n=30) or sitagliptin 100 mg once a day (n=30) in about 12 weeks. The main endpoints were the measurement of glycosylated hemoglobin (HbA1c %), fasting plasma glucose (FPG)(mg/dL), 2-hour post-meal glucose (PMG), and lipid profile. The safety of sitagliptin was assessed as a secondary endpoint. Results: The average changes from baseline of FPG, 2-hour PMG, HbA1C, and BMI were noticeably declined in the sitagliptin group compared to the placebo group (P<0.001). Furthermore, the changes in low-density lipoprotein (LDL-c) were noticeably lesser in the sitagliptin arm compared to the placebo arm after adjusting for confounding factors (P=0.011). The outbreak of harmful effects, hypoglycemia, urinary and genital infection, and hypovolemia did not differ among groups (P>0.05). Conclusion: Sitagliptin with insulin/metformin treatment gives rise to better augmentation in glycemic and lipid profiles without weight gain and hypoglycemic effects in overweight and obese Iranian populations with inadequate diabetes control. The favorable impacts of sitagliptin on lipid profiles, amelioration in glycemic indices, and decrement in BMI suggest that sitagliptin is a safe medication for cardiovascular happenings, which is an important issue in the production of antidiabetic pharmaceutics. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| sitagliptin.pdf | 1403/10/18 | 724185 | دانلود |
| article1.pdf | 1403/10/18 | 188747 | دانلود |
